3438-16-2Relevant articles and documents
Synthesis and antioxidant activities of berberine 9-: O -benzoic acid derivatives
Liu, Yanfei,Long, Shuo,Zhang, Shanshan,Tan, Yifu,Wang, Ting,Wu, Yuwei,Jiang, Ting,Liu, Xiaoqin,Peng, Dongming,Liu, Zhenbao
, p. 17611 - 17621 (2021/05/29)
Although berberine (BBR) shows antioxidant activity, its activity is limited. We synthesized 9-O-benzoic acid berberine derivatives, and their antioxidant activities were screened via ABTS, DPPH, HOSC and FRAP assays. The para-position was modified with halogen elements on the benzoic acid ring, which led to an enhanced antioxidant activity and the substituent on the ortho-position was found to be better than the meta-position. Compounds 8p, 8c, 8d, 8i, 8j, 8l, and especially 8p showed significantly higher antioxidant activities, which could be attributed to the electronic donating groups. All the berberine derivatives possessed proper lipophilicities. In conclusion, compound 8p is a promising antioxidant candidate with remarkable elevated antioxidant activity and moderate lipophilicity.
A cyclotrimethoxone-substituted salicylate compound and anti-tumor effect thereof
-
Paragraph 0032-0034, (2017/07/19)
The invention relates to the technical field of medicines, and designs and synthesizes a novel A cyclotrimethoxy 4'-hydroxyflavone compound and an A cyclotrimethoxone-substituted salicylate compound. The figure 1 is a general formula of the A cyclotrimethoxone-substituted salicylate compound, wherein in the formula, R1, R2 and R3 are equal to OCH3 or R2, R3 and R4 are equal to OCH3; R5- is equal to OCH3, CH3, F, Cl, Br, I or the like. The novel A cyclotrimethoxy 4'-hydroxyflavone compound and the A cyclotrimethoxone-substituted salicylate compound can have an obvious inhibiting effect on MGC-803 (human gastric carcinoma cells), HepG2 (human hepatoma carcinoma cells), MCF-7 (human breast cancer cells) and hopefully become anti-tumor drugs. The invention discloses a preparation method of the novel A cyclotrimethoxy 4'-hydroxyflavone compound and the A cyclotrimethoxone-substituted salicylate compound.
Synthesis technology of glibenclamide intermediate 5-chloro-2-methoxyben zoic acid
-
Paragraph 0012; 0013, (2017/03/08)
The invention provides a synthesis technology of a glibenclamide intermediate 5-chloro-2-methoxyben zoic acid. 5-chloro salicylic acid serves as raw materials. The synthesis technology is characterized by including the following steps that 300-400 kg of a sodium hydroxide solution with the mass friction being 20-40% and 30 kg of 5-chloro salicylic acid are sequentially added into a reaction tank, 80-100 kg of dimethyl sulfate is added dropwise after the mixture is uniformly stirred, temperature is raised to 30-40 DEG C, a reaction lasts for 3-4 h, heating reflux lasts for 4 h, reacting liquid is cooled to room temperature, acidification is performed through a hydrochloric acid solution with the concentration being 20-30% till pH is equal to 2-4, vacuum filtration is performed, a 5-chloro-methyl-2-methoxybenzoate wet product is obtained and placed in a drying oven, drying is performed at 35 DEG C, and the yield is 80-90%. The synthesis technology of glibenclamide intermediate 5-chloro-2-methoxyben zoic acid has the advantages that the intermediate 5-chloro-2-methoxyben zoic acid is an important intermediate for synthesizing glibenclamide, technological operation is easy, the technology is suitable for industrial production operation, and the product yield is stable.